Aldeyra Therapeutics
Stock Forecast, Prediction & Price Target
Aldeyra Therapeutics Financial Estimates
Aldeyra Therapeutics Revenue Estimates
Aldeyra Therapeutics EBITDA Estimates
Aldeyra Therapeutics Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $32.69M Low: $17.17M High: $61.79M avg. 0% | Avg: $74.63M Low: $65.33M High: $92.08M avg. 128.26% | Avg: $113.90M Low: $99.69M High: $140.51M avg. 52.60% | Avg: $174.40M Low: $152.65M High: $215.16M avg. 53.11% |
Net Income
% change YoY
| $-59.25M N/A | $-61.36M -3.56% | $-37.54M 38.82% | Avg: $-29.86M Low: $-53.04M High: $26.52M avg. 20.45% | Avg: $12.24M Low: $-33.00M High: $76.62M avg. 141.01% | Avg: $30.84M Low: $25.84M High: $40.21M avg. 151.82% | Avg: $70.53M Low: $59.10M High: $91.96M avg. 128.66% |
EBITDA
% change YoY
| $-56.03M N/A | $-60.33M -7.66% | $-35.20M 41.64% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.1 N/A | -$1.05 4.54% | -$0.64 39.04% | Avg: -$0.49 Low: -$0.9 High: $0.45 avg. 23.69% | Avg: $0.22 Low: -$0.56 High: $1.3 avg. 144.02% | Avg: $0.52 Low: $0.44 High: $0.68 avg. 143.40% | Avg: $1.2 Low: $1 High: $1.56 avg. 128.66% |
Operating Expenses
% change YoY
| $56.21M N/A | $62.67M 11.49% | $42.79M -31.72% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Aldeyra Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 110.49% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -53.04M, average is -29.86M and high is 26.52M.
What is Aldeyra Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 58.49% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $17.17M, average is $32.69M and high is $61.79M.
What is Aldeyra Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 109.94% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$0.9, average is -$0.49 and high is $0.45.
What is the best performing analyst?
In the last twelve months analysts have been covering Aldeyra Therapeutics stock. The most successful analyst is Justin Kim.